NAS:CRVS (USA) Also Trade In: Germany

Corvus Pharmaceuticals Inc $ 3.93 -0.16 (-3.91%)

Volume:
128,436
Avg Vol (1m):
307,880
Market Cap $:
110.18 Mil
Enterprise Value $:
53.69 Mil
P/E (TTM):
0.00
P/B:
2.17
Warning! GuruFocus has detected 1 Severe warning sign with CRVS. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Corvus Pharmaceuticals Inc () from 2016 to Sep 30 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Corvus Pharmaceuticals stock (CRVS) PE ratio as of Sep 30 2020 is 0. More Details

Corvus Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Corvus Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1175
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Corvus Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-09-300.0 2020-07-290.0
2020-09-290.0 2020-07-280.0
2020-09-280.0 2020-07-270.0
2020-09-250.0 2020-07-240.0
2020-09-240.0 2020-07-230.0
2020-09-230.0 2020-07-220.0
2020-09-220.0 2020-07-210.0
2020-09-210.0 2020-07-200.0
2020-09-180.0 2020-07-170.0
2020-09-170.0 2020-07-160.0
2020-09-160.0 2020-07-150.0
2020-09-150.0 2020-07-140.0
2020-09-140.0 2020-07-130.0
2020-09-110.0 2020-07-100.0
2020-09-100.0 2020-07-090.0
2020-09-090.0 2020-07-080.0
2020-09-080.0 2020-07-070.0
2020-09-070.0 2020-07-060.0
2020-09-040.0 2020-07-030.0
2020-09-030.0 2020-07-020.0
2020-09-020.0 2020-07-010.0
2020-09-010.0 2020-06-300.0
2020-08-310.0 2020-06-290.0
2020-08-280.0 2020-06-260.0
2020-08-270.0 2020-06-250.0
2020-08-260.0 2020-06-240.0
2020-08-250.0 2020-06-230.0
2020-08-240.0 2020-06-220.0
2020-08-210.0 2020-06-190.0
2020-08-200.0 2020-06-180.0
2020-08-190.0 2020-06-170.0
2020-08-180.0 2020-06-160.0
2020-08-170.0 2020-06-150.0
2020-08-140.0 2020-06-120.0
2020-08-130.0 2020-06-110.0
2020-08-120.0 2020-06-100.0
2020-08-110.0 2020-06-090.0
2020-08-100.0 2020-06-080.0
2020-08-070.0 2020-06-050.0
2020-08-060.0 2020-06-040.0
2020-08-050.0 2020-06-030.0
2020-08-040.0 2020-06-020.0
2020-08-030.0 2020-06-010.0
2020-07-310.0 2020-05-290.0
2020-07-300.0 2020-05-280.0

Corvus Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries C17.Germany CRVS.USA
Address 863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing small-molecule and antibody agents that target the immune system to treat patients with cancer. The firm's pipeline includes CPI-006, CPI-818, CPI-935, and others.